

JANNEY MONTGOMERY SCOTT

Life Sciences Newsletter

February 2016



Investment Banking

Richard Page (212) 829-3828
Head of Healthcare Investment Banking
rpage@janney.com

James McNaughton (215) 665-6032
Managing Director
jmcnaughton@janney.com

Benjamin McKean (215) 665-4474
Associate
bmckean@janney.com

Daniel Morrison (215) 665-6292
Analyst
dmorrison@janney.com

Equity Capital Markets

William Corkhill (617) 557-2970
Managing Director
wcorkhill@janney.com

David Lau (617) 557-2971
Managing Director
dlau@janney.com

Katherine O'Brien (617) 557-2979
Analyst
katherineobrien@janney.com

Equity Research

Paul Knight, CFA (212) 888-2696
Life Sciences Technology
pknight@janney.com

Roy Buchanan, Ph.D. (212) 940-6985
Biotechnology
rbuchanan@janney.com

Debjit Chattopadhyay, Ph.D. (215) 665-6224
Biotechnology
dchattopadhyay@janney.com

Ken Trbovich, CFA (215) 665-6290
Specialty Pharmaceuticals
ktrbovich@janney.com

Sales and Trading

Brian Donohue (212) 759-6211
Managing Director
bdonohue@janney.com

INSIDE THIS ISSUE

Notes from Janney's Life Sciences Technology Research Analyst, Paul Knight, CFA

- RGEN: 4Q "Briefcase": Beat and Better Visibility
- FMI: 4Q15 "Briefcase": OpEx Outpacing Topline
- WST: 4Q "Briefcase": West Backlog Going Way North
- A: 1Q "Briefcase": Still Beating, Still an Enigma
- TTOO: 4Q "Briefcase": More Clinics, Slower Uptake
- MLAB: Visit to our Lab Tool Company out West
- WST: Amgen's CZ Selection
- BRKR: 4Q "Briefcase": People Behind Another EPS Beat
- MLAB: Mesa - Biologic QC - Initiating with a Buy
- CDNA: CareDx - More than Peers, Initiating with Buy

Notes from Janney's Biotechnology Research Analyst, Roy Buchanan, Ph.D.

- ALDX: Positive AC Phase 2 Bodes Well for NS2 Pipeline
- CORT: Diversifying Beyond Cushing's, Investors Focus on the Platform
- XLRN: Phase 3 Trials on Track and Robust Cash Position, Upgrading to Buy
- GERN: IMbark and IMerge on Track; Business Development Efforts Continue
- EDIT: Trying to Cut in the Line to Cures; Initiating at Buy
- CLVS: AdCom for Rocilitanib, Still Like the Prospects for Approval
- SGMO: With \$210M Cash, SGMO Set to Initiate 1st of Many Gene Editing Clinical Trials
- SGMO: Second Genome Editing IND Cleared by FDA; Bodes Well For the Entire Program

Notes from Janney's Biotechnology Research Analyst, Debjit Chattopadhyay, Ph.D.

- BLUE: Gene therapy (GT) Better Positioned in a Value-based Pricing Environment
- CMRX: Time to Explore Strategic Alternative - Lowering FV to \$7
- MGNX: Taking on Cancer with DARTs and TRIDENTs - Initiating with Buy
- SBBP: Fundamentally Well-Positioned in a Schizophrenic Biotech Tape
- BLUE: Upcoming CALD Data a Test of Sentiment
- NKTR: "A Nickel ain't worth a Dime Anymore"
- CEMP: Sector Doldrums Creating Asymmetric Risk/Reward Potential
- NKTR: Taming, Harnessing and Unleashing IL-2
- QURE: Hemophilia B Data Gradually Driving Investor Interest

Notes from Janney's Specialty Pharmaceuticals Research Analyst, Ken Trbovich, CFA

- BDSI: BDSI Analyst Day Does Not Alter Our View
- CARA: Clinical Hold – Slows Pain But Pruritus a Go
- DEPO: Record Quarter Does Not Surprise to Upside
- DEPO: Worth a Trade for Monday's Earnings
- FLXN: Raising Fair Value Est. on Positive Phase 3
- AGRX: Capital Sufficient to Fund Ops into 2018
- DEPO: Ruling Increases Settlement Potential by March



PAUL KNIGHT, CFA – LIFE SCIENCES TECHNOLOGY RESEARCH ANALYST

RGEN: 4Q "Briefcase": Beat and Better Visibility

- February 25, 2016 – Repligen announced the extension of key long-term supply agreements with GE in conjunction with its 4Q15 earnings. Locking GE into a LT agreement provides increased revenue visibility, impedes competitors from entering the space, and allows Repligen to streamline operations. We maintain our BUY rating and FV of \$33. ([Link to Report](#))

FMI: 4Q15 "Briefcase": OpEx Outpacing Topline

- February 24, 2016 – FMI continues investing very heavily in OpEx (\$100m of burn relative to ~\$50m of 2016 Clinical sales) as it looks to create a market leading position in the diagnostics market. The launch of a liquid-based test, a universal companion Dx, and the entrance into international markets represent new market opportunities, but revenue growth continues to decelerate. ([Link to Report](#))

WST: 4Q "Briefcase": West Backlog Going Way North

- February 18, 2016 – Earnings were about the only in-line aspect of West's Q4 results. Organic growth of 9.7% beat our estimates by 300 bps. More stunning, backlog growth of 29% in the largest division, Packing Systems, makes 2016 guidance look conservative. Biologic production and packing is the fastest growing segment of Life Science, and West Pharmaceutical should be a core mid-cap holding. ([Link to Report](#))

A: 1Q "Briefcase": Still Beating, Still an Enigma

- February 17, 2016 – Didier Hirsch, CFO of Agilent is now like the CEO and taking pages from the MettlerToledo guidebook and providing enigmatic guidance. Beating every line in the January quarter, Agilent guided the fiscal year down by \$0.04 even though Fx is closer to a \$0.03 hurt and no impact on today's Fx rates. Oh well, it's better than the past practice of aggressive guidance. Continuing to cut costs and buy shares with free cash flow, this stock should be a core holding. ([Link to Report](#))

TTOO: 4Q "Briefcase": More Clinics, Slower Uptake

- February 17, 2016 – TTOO delivered on its 2015 goal of 30 instrument contracts, but conversions were slower than we estimated. The T2Bacteria clinical trial began enrollment and represents a major growth opportunity for this nascent company. Lumped in with the BioTech and Dx sell-off, we continue to see long-term value for this uniquely positioned Dx. We maintain our BUY rating, but reduce our FV to \$13. ([Link to Report](#))

MLAB: Visit to our Lab Tool company out West

- February 16, 2016 – We visited Mesa Labs (MLAB) last week and its business appears more compelling than ever with 80%+ recurring revenue and almost 60-70% of revenue part of FDA protocols for biopharmaceutical, medical device, and clinical safety testing. ERP implementation is done, the balance sheet has M&A capacity, and the factory floor was busy. Reminding us of a small-cap Mettler-Toledo or Thermo-Fisher, MLAB is underfollowed and undervalued. We initiated coverage last week with a Buy and Fair Value of \$106. ([Link to Report](#))

WST: Amgen's CZ Selection

- February 16, 2016 – Friday's announcement that Amgen chose West's Crystal Zenith (CZ) vials for its FDA-approved IMLYGIC therapy is another important milestone for the company. As we highlighted in our initiation report last month, the FDA recalls in 2010-2011 because of glass particulates represents a long-term opportunity for West's CZ to displace glass vials. We maintain our BUY rating and \$69 FV. ([Link to Report](#))

BRKR: 4Q "Briefcase": People Behind Another EPS Beat

- February 11, 2016 – It's all about the change in Bruker's managers and its Board of Directors. It also helps that it has a near-monopoly in NMR instrument technology (3D imaging of molecules) after Agilent left the business in 2014 and Bruker raised prices in early 2015. Bruker beat estimates in 4Q15 and we expect more beats in 2016. We raise our Fair Value to \$26. ([Link to Report](#))

MLAB: Mesa - Biologic QC - Initiating with a Buy

- February 9, 2016 – Reminding us of a small-cap Mettler-Toledo or Thermo-Fisher, Mesa Laboratories (MLAB) provides instruments, consumables, and other products for safety testing and quality control. About 70% of sales are to healthcare markets, with biopharmaceutical and medical device testing most significant. Led by a former Varian executive, John Sullivan, as CEO, the company is also deploying strategic M&A to drive 10-20% annual earnings growth. Underfollowed and undervalued, we initiate coverage with a Buy and Fair Value of \$106 per share. ([Link to Report](#))

CDNA: CareDx - More than Peers, Initiating with Buy

- February 9, 2016 – Falling in sympathy with its small-cap diagnostic peers, CareDx is unlike most peers and has significantly more upside potential. CareDx has an established business with its market leadership in transplant diagnostics. M&A and clinical data catalysts are occurring over the next four months and its balance sheet is funded. We initiate coverage with a Buy rating and a Fair Value of \$12. ([Link to Report](#))



ROY BUCHANAN, PH.D. – BIOTECHNOLOGY RESEARCH ANALYST

ALDX: Positive AC Phase 2 Bodes Well for NS2 Pipeline

- February 29, 2016 – Aldeyra reported positive top-line data for the phase 2a study for NS2 in allergic conjunctivitis (AC). Despite not being designed as an efficacy study, NS2 hit vs. placebo on two important measures, itching and tearing. Next steps will depend on discussions with thought-leaders and the uveitis phase 2, which has completed its last visit with data expected in 2Q. We increase our fair value on Aldeyra to \$25 (from \$15) on the positive implications for NS2 anti-inflammatory activity. ([Link to Report](#))

CORT: Diversifying Beyond Cushing's, Investors Focus on the Platform

- February 29, 2016 – We recently met with investors and Corcept management. While Korlym in Cushing's was certainly discussed, the focus of the meetings tended to be on the broader GRinhibition platform, opportunities in oncology and metabolic syndromes, for example, as well as a Cushing's follow-on. Data is expected at ASCO in early June, which could bolster the outlook in oncology. We remain encouraged by the company's novel library of compounds, the potential for 2 INDs filed by YE, and supporting cash from Korlym, and reiterate our Buy rating on Corcept. ([Link to Report](#))

XLRN: Phase 3 Trials on Track and Robust Cash Position, Upgrading to Buy

- February 29, 2016 – Acceleron ended 2015 with \$136M in cash. Following the 1Q16 equity financing for \$140M net, the company projects cash into 2H19. We're upgrading to Buy from Neutral with about 60% upside to our current fair value, which doesn't include Celgene-funded sotatercept or the muscle programs, and could be conservative in our MDS assumptions (19% RS+ vs. ~50% according to XLRN). We also look forward to the dalantercept data in mRCC by YE; we have a 30% probability of success (through phase 3) for dalantercept in mRCC. Our fair value lowers to \$39 from dilution (from \$45). ([Link to Report](#))

GERN: IMbark and IMerge on Track; Business Development Efforts Continue

- February 26, 2016 – For 2015, Geron reported \$36.4 M in revenues, \$8.9 M in operating expenses and year end cash and cash equivalents of \$146.7 M. The company reported that IMbark and IMerge, its Phase 2 programs in partnership with Janssen are on track with more than 75 sites active and first data readout expected in 2017. The company continues its quest for an appropriate business transaction to complement imetelstat. We continue to view imetelstat as a differentiated and effective hem/onc agent and look forward to an appropriate, if not risk-free, acquisition, and reiterate our BUY rating on the shares. ([Link to Report](#))

EDIT: Trying to Cut in the Line to Cures; Initiating at Buy

- February 25, 2016 – We're initiating coverage on Editas with a Buy rating and \$48 fair value. We think genome editing is here to stay and that first-mover advantage (with CRISPR) and strong management and scientific advisors set Editas up for success. The total market for genome editing should accommodate multiple players, in fact there is almost no overlap in our valued indications for Editas and that for established leader Sangamo (Buy, \$15 FV). Partnerships, IP developments, and pre-clinical and clinical data are the largest drivers for 12-36 months, in our view. ([Link to Report](#))

CLVS: AdCom for Rociletinib, Still Like the Prospects for Approval

- February 12, 2016 – Clovis announced this morning an Advisory Committee for rociletinib in 2nd-line T790M+ NSCLC on April 12th. Not surprising given management's recent comments suggesting the possibility of a panel. We think this will end up being a positive as we expect a panel to vote in favor of the drug's activity and safety. The announcement may pressure shares, but we're still expecting an approval by the June 28th PDUFA and would be buyers. We expect Clovis to report earnings the last week of February. We reiterate our Buy rating and \$50 fair value. ([Link to Report](#))

SGMO: With \$210M Cash, SGMO Set to Initiate 1st of Many Gene Editing Clinical Trials

- February 10, 2016 – For 4Q15/FY15, Sangamo reported YE cash of \$210M, and highlighted recent regulatory progress including the clearance of two IVPRP INDs. For 2016, the company plans to initiate the first ever in vivo genome editing trials, in hemo B and MPS I by mid-2016, file 6 additional IVPRP INDs, and present data updates on the LSD and HIV programs this half. We remain Buy rated and look to early data from the IVPRP program by YE2016 and/or a T-cell partnership as important catalysts. ([Link to Report](#))

SGMO: Second Genome Editing IND Cleared by FDA; Bodes Well For the Entire Program

- February 8, 2016 – Sangamo announced that the FDA has cleared the IND for ZFN-mediated genome editing treatment of MPS I. This is the second IND from the company's In Vivo Protein Replacement Platform (IVPRP) to be cleared by the FDA. We think that this event not only increases the IND clearance likelihood of the other IVPRP programs, but should also help increase investor confidence in the platform. As we await phase I Hemophilia B and additional phase II HIV/AIDS data this year, we reiterate our confidence in Sangamo's platform and our BUY rating. ([Link to Report](#))



DEBJIT CHATTOPADHYAY, PH.D. – BIOTECHNOLOGY RESEARCH ANALYST

BLUE: Gene therapy (GT) Better Positioned in a Value-based Pricing Environment

- February 22, 2016 – Since 1995, cancer drug prices increased by 10% annually and there appears to be no correlation between price and benefit. A recent article (Journal of Economic Perspectives 29: 139-162; 2015) points to price per life-year gained, has increased from \$54K in 1995 to \$207K in 2013 (adjusted for inflation, in 2013 dollars). With IO combinations phrases like "financial-toxicity" and "value-based-pricing" are here to stay. Hence, GT even with transient benefits (lasting up to five years) offers compelling alternatives to conventional therapies. ([Link to Report](#))

CMRX: Time to Explore Strategic Alternative - Lowering FV to \$7

- February 22, 2016 – The updated data from the SUPPRESS study potentially relegates brincidofovir to a niche market at best. Over the near-term, Chimerix is back to the drawing board tinkering with formulation prior to making clinical headway. However, the ~\$340M cash on its balance sheet should allow Chimerix to look beyond its internal pipeline and core-competence, take advantage of the broader sector pullback (XBI and IBB down 28% and 22%, YTD), and potentially acquire compelling mid-stage assets aimed at initiating a turnaround. ([Link to Report](#))

MGNX: Taking on Cancer with DARTs and TRIDENTs - Initiating with Buy

- February 17, 2016 – While the sector is likely to remain challenged as political rhetoric drives sentiment, investors with a longer term outlook might find MacroGenics appealing at current levels. Trading at a modest multiple to cash, but with eight clinical programs spanning numerous oncology/immunology indications, supported by a validated platform that is poised to generate multiple INDs over the foreseeable future, and a robust balance sheet, we rate MacroGenics as a compelling small cap idea for the next 12 to 24 months. ([Link to Report](#))

SBBP: Fundamentally Well-Positioned in a Schizophrenic Biotech Tape

- February 8, 2016 – Cash accounts for 73% of Strongbridge's current market cap, thus significantly discounting its ongoing pivotal study and two phase 2 assets, which together address unmet clinical opportunities in neuro-endocrinology (Cushing's and Acromegaly). With the likely advent of a value-based pricing, lead asset COR-003 (Cushing's) is differentiated based on its activity profile, while the emergent safety profile of COR-005 could be a value driver in the ~\$1B global Acromegaly segment. ([Link to Report](#))

BLUE: Upcoming CALD Data a Test of Sentiment

- February 8, 2016 – Preliminary read from the potentially pivotal adrenoleukodystrophy (ALD) study is expected in April (abstracts in March). While our \$2 NPV is a reflection of the rarity of the condition, the readout could have an out-sized impact on sentiment. Key points: Impact of age and baseline status on outcomes; Disease stabilization akin to HSCT without its associated morbidity/mortality; VLCFA post treatment (could prevent AMN in the future); Neurological Function Score (limited historic precedence); and Correlation of (VCN, cell count) with outcomes. ([Link to Report](#))

NKTR: "A Nickel ain't worth a Dime Anymore"

- February 8, 2016 – The recent sell-off (in-line with peers) offers compelling entry points ahead of five pivotal data readouts across its partnered pipeline over the next 12 months. Importantly, its commercial portfolio (Movantik and Adynovate) potentially supports current \$1.5B EV (7x multiple on 2020 royalty estimate of \$380M discounted at 12%); however, key to 2016 stock performance is likely to be NKTR-214, and should the ongoing dose-escalation study point to marked improvements over IL-2's clinical profile (safety and or efficacy), we see upside to our FV. ([Link to Report](#))

CEMP: Sector Doldrums Creating Asymmetric Risk/Reward Potential

- February 1, 2016 – With the bulk of its clinical risk in the rear view, it is likely solithromycin will be approved for the treatment of CAP, transient ALT elevations unlikely to curb commercial opportunity especially in the community setting (90% of the market is for oral therapy), a concentrated prescriber base, and a pipeline in a product potential beyond CAP – Cempra is trading at a lower EV than some of the recent peer acquisitions (OPTR, and DTRX), while potentially addressing significantly larger market opportunities. Recommend buying at current levels. ([Link to Report](#))

NKTR: Taming, Harnessing and Unleashing IL-2

- January 27, 2016 – We initiate on Nektar with a Buy and a FV estimate of \$21. In volatile markets Nektar's commercial portfolio offers a degree of stability, with potential for significant alpha capture from its IO platform led by NKTR-214. NKTR-214 data during 3Q16 could set the stage for clinical expansion, especially in combination with checkpoint inhibitors driving partnering interest. Based on its commercial and partnered pipeline, we estimate downside on a NKTR-214 disappointment to ~\$10, with upside significantly higher than our FV estimate. ([Link to Report](#))

QURE: Hemophilia B Data Gradually Driving Investor Interest

- January 25, 2016 – SMID-cap biotechnology has had a rough start to the year (XBI -19.5%), and the out-of-favor gene therapy segment down by ~27%; however, on the back of early but promising data in Hemophilia B, uniQure has begun to differentiate and is up about 5.3%. With full cohort data expected during 2Q16, second cohort dosing expected to begin during February, and additional catalysts during 2H16, uniQure offers attractive entry points (EV ~\$185M) for long-term investors in a sector, which is positioned to deliver compelling alternatives to chronic therapy. ([Link to Report](#))



KEN TRBOVICH, CFA – SPECIALTY PHARMACEUTICALS RESEARCH ANALYST

BDSI: BDSI Analyst Day Does Not Alter Our View

- February 26, 2016 – BDSI hosted its analyst day yesterday, highlighting the benefits of the TennCare contract win for Bunavail and detailing the potential for Belbuca, which was launched earlier this week by BDSI's partner Endo International (ENDP, not covered). References to planned R&D investments and operating expense levels do not significantly alter our expectations for the business in 2016 and beyond. We remain concerned about the level of BDSI's burn relative to minimal success thus far in its own launch of Bunavail that began in late 2014. Royalties on Belbuca are not enough to offset this in 2016-2017. ([Link to Report](#))

CARA: Clinical Hold – Slows Pain But Pruritus a Go

- February 26, 2016 – CARA announced it halted the Phase 3 adaptive pain trial because a pre-specified safety stop was triggered. This led to implementation of a protocol hold by the FDA. It appears the problem can be addressed in a manner that will enable CARA to continue development of IV-CR845 in pain because the concerns pertain to the highest dose and have not been seen at either of the two lower doses in the same study. We believe this will not have any impact for planned Phase 3 studies in uremic pruritus (UP). ([Link to Report](#))

DEPO: Record Quarter Does Not Surprise to Upside

- February 23, 2016 – Depomed reported record results that were in-line with consensus estimates (reported revenues of \$111.1 mln compared to consensus estimates of \$111.3), but short of our expectations for a positive surprise (\$117 mln). Though the quarter was strong, management did acknowledge slight channel inventory build (3-days on key products). Guidance was also in-line with consensus views with the mid point of the guided range \$505 mln matching existing consensus views. ([Link to Report](#))

DEPO: Worth a Trade for Monday's Earnings

- February 19, 2016 – Attacks on the short side have come as DEPO became the subject of an inter-partes review filed, in part, by a firm whose CEO is referred to by others he has targeted as a "shakedown artist" and a "patent troll."* Then there have been the doubts raised by other analysts questioning "seller's rebates" and their potential impact on 4Q15 results while raising doubts not just about the outlook for the quarter, but all of 2016. We remain focused on the fundamental execution of the business, and from where we sit, the business looks very good. ([Link to Report](#))

FLXN: Raising Fair Value Est. on Positive Phase 3

- February 17, 2016 – FLXN reported its Phase 3 study of Zilretta achieved its primary endpoint with highly significant results (detailed below). We see this as a major catalyst for the stock since it removes the worst case scenario (failure as seen recently with a competitor) and significantly reduces uncertainty that arose when Zilretta came up short with the same endpoint in an earlier Phase 2B study last September. The results are a significant achievement on the path toward potential FDA approval and launch of Zilretta in 1H17. ([Link to Report](#))

AGRX: Capital Sufficient to Fund Ops into 2018

- February 10, 2016 – Recent meetings with management of Agile and Corium (CORI, not covered), its manufacturing partner, serve as a reminder of uniqueness of Twirla and the manufacturing facility previously constructed to produce the product. Recently completed financing should fund AGRX into 2018, well beyond the expected results of the ongoing Phase 3 trial in 4Q16, filing of these results as supplement to the NDA in 1H17 and to potential approval six months thereafter. ([Link to Report](#))


DEPO: Ruling Increases Settlement Potential by March

- February 8, 2016 – We see the decision from the District Court in favor of DEPO's claims construction as increasing DEPO's likelihood of prevailing in its ongoing patent dispute with generic filers and thereby increasing its negotiating power in settlement discussions as well. The majority of ANDA cases end in settlement. With the trial set to begin on March 9th, we see the Markman decision as increasing the likelihood of a settlement occurring in the next month. ([Link to Report](#))




MACRO AND INDUSTRY UPDATE

Life Sciences Industry Performance



Source: FactSet Research Systems, as of February 26, 2016

CBOE Volatility S&P 500 Index (VIX) and Equity Issuance




Source: BioCentury Publications and FactSet Research Systems, as of February 26, 2016
 Excludes deals with total proceeds of greater than \$1 billion



MACRO AND INDUSTRY UPDATE (CONT'D)

High Frequency of Single Day Sell-offs Greater than 200 Points




Source: BioCentury Publications and FactSet Research Systems, as of February 26, 2016




INITIAL PUBLIC OFFERING MARKET UPDATE

Annual Initial Public Offering Activity



Source: BioCentury Publications, FactSet Research Systems, Ipreo, Private Raise and SEC filings as of February 26, 2016

Quarterly Initial Public Offering Backlog




Source: BioCentury Publications, FactSet Research Systems, Ipreo, Private Raise and SEC filings as of February 26, 2016




INITIAL PUBLIC OFFERING MARKET UPDATE (CONT'D)

2015 / 2016 Initial Public Offerings Performance (Offer to Current)



Source: BioCentury Publications, FactSet Research Systems, Ipreo, Private Raise and SEC filings as of February 26, 2016

2015 / 2016 Initial Public Offerings Valuations (Pre- and Post-Money)




Source: BioCentury Publications, FactSet Research Systems, Ipreo, Private Raise and SEC filings as of February 26, 2016



INITIAL PUBLIC OFFERING MARKET UPDATE (CONT'D)

Initial Public Offering Pricing Statistics Relative to Initial Filed Range



Source: BioCentury Publications, FactSet Research Systems, Ipreo, Private Raise and SEC filings as of February 26, 2016

Initial Public Offerings – Since 7/1/15

(Values in millions, except per share data)																	
Date	Company	Ticker	Stage	Shares		Price			Insider	% of 52	Valuation		% Change Since Offering				
				Initial	Offered	Initial	Offer	Current			Pre-IPO	Post-IPO	Initial	1 Day	1 Week	Current	
2/11/2016	Proteostasis Therapeutics, Inc.	PTI	Pre-clinical	3.9	6.3	\$12.00 - \$14.00	\$8.00	\$6.00	\$50.0	40.4%	75.0%	\$100.1	\$150.1	-38.5%	-17.0%	-29.4%	-25.0%
2/10/2016	AveXis, Inc.	AVXS	Phase 1	4.3	4.8	\$19.00 - \$21.00	20.00	19.52	95.0	20.0%	95.8%	316.0	411.0	0.0%	-9.7%	-7.3%	-2.4%
2/2/2016	Beigene Ltd	BGNE	Phase 1	5.5	7.6	\$22.00 - \$24.00	24.00	28.95	182.2	39.8%	81.3%	572.2	754.4	4.3%	18.0%	12.0%	20.6%
2/2/2016	Editas Medicine Inc.	EDIT	Development	5.9	6.8	\$16.00 - \$18.00	16.00	23.95	108.6	0.0%	81.5%	476.8	585.4	-5.9%	13.8%	-18.2%	49.7%
11/19/2015	Axsome Therapeutics, Inc.	AXSM	Phase 3	4.3	5.7	\$11.00 - \$13.00	9.00	7.89	51.0	0.0%	50.1%	121.2	172.2	-25.0%	-2.9%	-2.0%	-12.3%
11/11/2015	Wave Life Sciences Pte. Ltd	WVE	Pre-clinical	5.0	6.4	\$15.00 - \$17.00	16.00	14.70	102.0	31.4%	70.0%	232.9	334.9	0.0%	0.0%	-0.1%	-8.1%
11/10/2015	Advanced Accelerator Applications	AAP	Phase 3	4.7	5.4	\$15.00 - \$17.00	16.00	33.00	86.3	0.0%	97.1%	542.2	628.4	0.0%	53.1%	56.3%	106.3%
11/10/2015	Voyager Therapeutics, Inc.	VYGR	Phase 1	4.7	5.8	\$15.00 - \$17.00	14.00	9.99	80.5	0.0%	32.7%	294.5	375.0	-12.5%	26.8%	42.9%	-28.6%
11/4/2015	Kura Oncology	KURA	Phase 2	6.3	6.3	\$16.00 - \$16.00	8.00	4.85	50.0	0.0%	19.4%	116.1	166.1	-50.0%	-2.0%	8.7%	-39.4%
10/28/2015	MyoKardia, Inc.	MYOK	Phase 2	4.7	6.3	\$15.00 - \$17.00	10.00	7.15	62.5	16.6%	42.7%	208.1	270.6	-37.5%	5.3%	-11.0%	-28.5%
10/21/2015	Dimension Therapeutics, Inc.	DMTX	Pre-clinical	5.5	5.5	\$14.00 - \$16.00	13.00	6.92	71.5	55.9%	44.5%	251.9	323.4	-13.3%	-16.9%	4.0%	-46.8%
10/16/2015	StrongBridge BioPharma fka Cortendo	SBBP	Phase 3	4.3	2.5	\$10.00 - \$10.00	10.00	3.95	25.0	0.0%	21.1%	187.1	212.1	0.0%	-8.4%	-24.0%	-60.5%
10/14/2015	Cerecor Inc	CERC	Phase 2	4.2	4.0	\$6.00 - \$7.00	6.50	3.09	26.0	0.0%	61.8%	30.1	56.1	0.0%	-1.5%	4.5%	-52.5%
10/7/2015	CytomX Therapeutics, Inc.	CTMX	Pre-clinical	6.7	7.7	\$14.00 - \$16.00	12.00	13.35	92.0	18.7%	54.1%	339.0	431.0	-20.0%	7.5%	10.2%	11.3%
10/6/2015	Aclaris Therapeutics, Inc.	ACRS	Phase 2	5.0	5.8	\$14.00 - \$16.00	11.00	18.95	63.3	23.7%	55.9%	158.5	221.7	-26.7%	0.5%	30.5%	72.3%
10/1/2015	NovoCure, LTD	NVCR	Commercial	12.5	7.9	\$26.00 - \$29.00	22.00	10.80	165.0	0.0%	35.0%	1,653.9	1,818.9	-20.0%	-16.9%	-4.5%	-50.9%
9/30/2015	Edge Therapeutics, Inc.	EDGE	Phase 2	5.7	8.4	\$14.00 - \$16.00	11.00	7.04	92.5	29.7%	27.2%	222.0	314.5	-26.7%	17.6%	60.2%	-36.0%
9/30/2015	Mirna Therapeutics, Inc.	MIRN	Phase 1	4.7	6.3	\$13.00 - \$15.00	7.00	3.94	43.8	38.9%	35.8%	96.6	140.4	-50.0%	0.7%	-11.0%	-43.7%
9/17/2015	Nabiva Therapeutics AG	NBRV	Phase 2	6.0	10.4	\$15.00 - \$17.00	10.25	8.99	106.1	45.5%	51.4%	203.1	309.2	-35.9%	29.2%	-5.1%	-12.3%
9/17/2015	Penumra, Inc.	PEN	Commercial	3.8	4.6	\$25.00 - \$28.00	30.00	47.05	138.0	0.0%	79.3%	781.2	919.2	13.2%	37.7%	34.3%	56.8%
9/16/2015	REGENXBIO, Inc.	RGNX	Pre-Clinical	5.6	7.2	\$17.00 - \$19.00	22.00	13.04	159.4	0.0%	40.8%	419.1	578.5	22.2%	38.4%	20.1%	-40.7%
8/11/2015	Global Blood Therapeutics, Inc.	GBT	Phase 1/2	6.0	6.9	\$16.00 - \$18.00	20.00	14.93	138.0	0.0%	26.2%	436.2	574.2	17.6%	115.6%	120.8%	-25.4%
8/5/2015	Aimmune Therapeutics, Inc.	AIMT	Phase 2	8.3	11.5	\$14.00 - \$16.00	16.00	16.20	184.0	15.6%	57.2%	490.9	674.9	6.7%	50.6%	59.5%	1.3%
8/4/2015	Zynerba Pharmaceuticals, Inc.	ZYNE	Commercial	3.0	3.5	\$13.00 - \$15.00	14.00	5.94	48.3	40.0%	13.8%	80.3	128.6	0.0%	16.1%	128.9%	-57.6%
7/29/2015	vTv Therapeutics Inc	VTVT	Phase 2	7.8	7.8	\$15.00 - \$17.00	15.00	6.06	117.2	21.3%	43.3%	375.0	492.2	-6.3%	-27.4%	-36.7%	-59.6%
7/27/2015	NantKwest, Inc.	NK	Phase 1	7.0	9.5	\$20.00 - \$23.00	25.00	7.16	238.3	23.3%	18.6%	1,766.1	2,004.4	16.3%	38.6%	20.0%	-71.4%
7/22/2015	Neos Therapeutics, Inc.	NEOS	Commercial	4.0	5.5	\$14.00 - \$16.00	15.00	10.35	82.8	21.3%	35.7%	145.3	228.1	0.0%	30.3%	30.4%	-31.0%

Source: BioCentury Publications, FactSet Research Systems, Ipreo, Private Raise and SEC filings as of February 26, 2016



INITIAL PUBLIC OFFERING MARKET UPDATE (CONT'D)

Initial Public Offerings – Since 7/1/15 (cont'd)

(Values in millions, except per share data)				Shares		Price			Insider		% of 52	Valuation		% Change Since Offering			
Date	Company	Ticker	Stage	Initial	Offered	Initial	Offer	Current	Proceeds	Participation	Wk High	Pre-IPO	Post-IPO	Initial	1 Day	1 Week	Current
7/15/2015	Chiasma, Inc.	CHMA	Phase 3	5.4	7.3	\$13.00 - \$15.00	\$16.00	\$10.05	\$117.1	26.4%	32.9%	\$265.8	\$382.9	14.3%	25.0%	45.1%	-37.2%
7/15/2015	ProNai Therapeutics, Inc.	DNAI	Phase 2	6.7	9.3	\$14.00 - \$16.00	17.00	6.01	158.4	8.8%	17.8%	352.4	510.8	13.3%	81.2%	74.4%	-64.6%
7/1/2015	Natera, Inc.	NTRA	Commercial	6.3	10.8	\$15.00 - \$17.00	18.00	7.76	195.1	0.0%	31.9%	691.7	886.8	12.5%	26.3%	18.1%	-56.9%
7/1/2015	ConforMIS, Inc.	CFMS	Commercial	9.0	10.4	\$14.00 - \$16.00	15.00	9.23	155.3	0.0%	34.3%	451.3	606.5	0.0%	28.3%	46.8%	-38.5%
				Mean	5.7	6.9		\$15.06	\$106.0	16.7%		\$399.3	\$505.2	-8.0%	18.0%	21.6%	-19.7%
				Median	5.5	6.4		\$15.00	\$95.0	16.6%		\$294.5	\$382.9	0.0%	16.1%	12.0%	-31.0%
				High	12.5	11.5		\$30.00	\$238.3	55.9%		\$1,766.1	\$2,004.4	22.2%	115.6%	128.9%	106.3%
				Low	3.0	2.5		\$6.50	\$25.0	0.0%		\$30.1	\$56.1	-50.0%	-27.4%	-36.7%	-71.4%

Source: BioCentury Publications, FactSet Research Systems, Ipreo, Private Raise and SEC filings as of February 26, 2016

Current Initial Public Offering Backlog

(\$ in millions, except per share data)


Latest File Date	Initial File Date	Company	Ticker	Stage of Lead Program	# of Clinical Programs	Latest Filing				Valuation		
						Shares Filed	% Shares Outstanding	Filing Range	Amount Filed	Post Money Last Round	Pre Money	Implied Step Up
2/26/2016	2/26/2016	Todos Medical Limited	-	Pre-clinical	-	-	-	-	\$53.3	N/A	-	-
2/26/2016	1/15/2016	Oncobiologics, Inc.	ONS	Phase 2	2	-	-	-	115.0	N/A	-	-
2/26/2016	1/4/2016	Syndax Pharmaceuticals Inc	SNDX	Phase 3	4	4.4	0.3	\$14.00 - \$16.00	66.0	98.1	\$194.6	2.0x
2/22/2016	8/25/2015	Advanced Inhalation Therapies Ltd.	AITP	Phase 2	1	0.7	0.3	\$15.00 - \$15.00	5.0	N/A	56.6	N/A
2/17/2016	9/19/2014	Exagen Diagnostics	EXDX	Commercial	-	-	-	-	69.0	20.0	-	-
2/16/2016	9/9/2015	AnaplysBio, Inc.	ANAB	Pre-clinical	-	-	-	-	86.3	63.6	-	-
2/12/2016	1/5/2016	Spring Bank Pharmaceuticals, Inc.	SBPH	Phase 2	3	-	-	-	57.5	N/A	-	-
2/10/2016	2/10/2016	Sensus Healthcare, Inc.	SRTS	Commercial	-	-	-	-	23.0	N/A	-	-
2/8/2016	8/31/2015	Sancilio Pharmaceuticals Company, Inc.	SPCI	Pre-clinical	-	-	-	-	86.3	N/A	-	-
2/8/2016	1/4/2016	Reata Pharmaceuticals, Inc.	RETA	Phase 2	9	-	-	-	80.0	N/A	-	-
2/8/2016	1/4/2016	Corvus Pharmaceuticals, Inc.	CRVS	Phase 1	1	-	-	-	115.0	172.0	-	-
2/5/2016	6/8/2015	Patheon N.V.	PTHN	Commercial	-	-	-	-	100.0	0.0	-	-
2/4/2016	3/26/2014	Mapi - Pharma Ltd.	MAPI	Phase 2	3	2.9	0.3	\$15.00 - \$17.00	50.0	N/A	124.7	N/A
2/3/2016	12/22/2015	Cancer Prevention Pharmaceuticals, Inc.	CPP	Phase 3	5	1.9	0.3	\$12.00 - \$14.00	25.0	27.5	71.5	2.6x
1/29/2016	10/5/2015	PLx Pharma Inc.	PLXP	Approved	6	3.8	0.4	\$17.00 - \$19.00	68.4	N/A	100.2	N/A
1/25/2016	1/25/2016	Tactile Systems Technology, Inc.	TCMD	Commercial	2	-	-	-	86.3	N/A	-	-
1/21/2016	10/19/2015	Merus B.V.	MRUS	Phase 1/2	1	-	-	-	60.0	53.0	-	-
1/8/2016	1/8/2016	Clearside Biomedical, Inc.	CLSD	Phase 3	3	-	-	-	57.5	79.0	-	-
1/5/2016	1/5/2016	Visterra, Inc.	VIST	Phase 2	1	-	-	-	69.0	81.1	-	-
1/4/2016	1/4/2016	Audentes Therapeutics, Inc.	BOLD	Pre-clinical	-	-	-	-	86.3	207.7	-	-
12/22/2015	12/22/2015	Pulse Biosciences, Inc.	PULBIO	Development	-	5.0	0.4	\$4.00 - \$4.00	20.0	N/A	30.3	N/A
11/25/2015	10/21/2015	Viventia Bio Inc.	VITA	Phase 3	2	-	-	-	86.3	N/A	-	-
11/5/2015	6/16/2015	Aeglea BioTherapeutics, Inc.	AGLE	Phase 1	4	-	-	-	86.3	26.1	-	-
11/3/2015	7/7/2015	GenSight Biologics S.A.	GNST	Phase 1/2	4	4.7	0.3	\$13.00 - \$15.00	65.1	104.4	190.5	1.8x
10/7/2015	8/26/2015	Acelity Holdings, Inc.	ACEH	Commercial	-	-	-	-	1,000.0	N/A	-	-
8/31/2015	8/31/2015	PharMEDium Healthcare Holdings, Inc.	PMHC	-	-	-	-	-	100.0	N/A	-	-
7/13/2015	6/16/2015	BioCardia, Inc.	BCDA	Phase 2	2	3.8	0.3	\$12.00 - \$14.00	50.0	132.9	95.7	0.7x
4/27/2015	2/11/2015	Klox Technologies Inc	KLOX	Commercial	3	4.8	0.2	\$13.00 - \$15.00	67.2	334.1	286.2	0.9x
4/27/2015	3/31/2015	Anterios, Inc.	ANTE	Pre-clinical	-	3.9	0.3	\$12.00 - \$14.00	50.7	0.0	124.9	-
3/9/2015	2/12/2015	Valeritas, Inc.	VLRX	Commercial	-	5.0	0.3	\$14.00 - \$16.00	75.0	107.9	161.8	1.5x
1/23/2015	12/23/2014	BeneChill, Inc.	BNCH	Commercial	-	-	-	-	13.8	N/A	-	-

Source: BioCentury Publications, FactSet Research Systems, Ipreo, Private Raise and SEC filings as of February 26, 2016




FOLLOW-ON MARKET UPDATE

Annual Follow-On Offering Activity



Source: BioCentury Publications, FactSet Research Systems, and SEC filings as of February 26, 2016

Quarterly Shelf Registrations




Source: FactSet Research Systems, Ipreo, Private Raise and SEC filings as of February 26, 2016




FOLLOW-ON MARKET UPDATE (CONT'D)

Traditionally Marketed Follow-On Pricing Statistics




Source: BioCentury Publications, FactSet Research Systems, Ipreo, Private Raise and SEC filings as of February 26, 2016

LTM Issuance by Sector (Deals)



LTM Issuance by Mkt. Cap.



Source: BioCentury Publications, FactSet Research Systems, Ipreo, Private Raise and SEC filings as of February 26, 2016



FOLLOW-ON MARKET UPDATE

Traditionally Marketed Follow-On Offerings – Since 7/1/15

(Values in millions, except per share data)				Filing	Offering			Pre Deal	Proceeds /			Current	% Change	% Change Since Offering		
	Date	Company	Ticker	Industry	Price	Shares	Price	Proceeds	Mkt. Cap.	Mkt. Cap.	3M ADTV	Price	File / Offer	1 Day	1 Week	Current
1.	2/4/2016	Quotient Ltd.	QTNT	Med Tech	\$11.41	4.4	\$9.00	\$40.0	\$239.2	16.7%	0.02	\$8.01	-21.1%	-16.9%	-11.2%	-11.0%
2.	2/3/2016	Jaguar Animal Health, Inc	JAGX	Large Pharma	2.48	2.0	2.50	5.0	20.1	24.8%	0.04	1.65	0.8%	-22.4%	-23.2%	-34.0%
3.	1/7/2016	Collegium Pharmaceutical, Inc.	COLL	Spec Pharma	25.51	2.8	20.00	55.0	527.7	10.4%	0.16	19.22	-21.6%	-1.4%	-22.2%	-3.9%
4.	1/7/2016	Ardelyx, Inc.	ARDX	Biotechnology	14.96	8.6	10.00	86.3	388.3	22.2%	0.16	9.84	-33.2%	7.2%	5.5%	-1.6%
5.	1/6/2016	Akebia Therapeutics, Inc.	AKBA	Biotechnology	12.56	7.3	9.00	65.3	384.9	17.0%	0.50	7.45	-28.3%	-3.8%	-10.7%	-17.2%
6.	1/6/2016	Adamas Pharmaceuticals Inc.	ADMS	Spec Pharma	27.91	2.5	23.00	57.5	514.0	11.2%	0.59	12.87	-17.6%	5.7%	11.1%	-44.0%
7.	1/6/2016	Prothena Corporation plc	PRTA	Biotechnology	58.99	2.3	53.00	119.3	1,859.5	6.4%	0.36	33.64	-10.2%	6.2%	-12.2%	-36.5%
8.	1/6/2016	Otonomy, Inc.	OTIC	Biotechnology	24.40	5.8	20.00	115.0	591.4	19.4%	0.28	13.73	-18.0%	5.5%	-11.4%	-31.4%
9.	1/6/2016	Epizyme, Inc.	EPZM	Biotechnology	15.12	15.3	9.00	138.0	631.0	21.9%	0.45	8.95	-40.5%	23.0%	17.2%	-0.6%
10.	1/6/2016	Cempra, Inc.	CEMP	Spec Pharma	28.73	4.2	24.00	100.0	1,263.1	7.9%	0.75	17.63	-16.5%	-7.7%	-10.6%	-26.5%
11.	1/6/2016	ACADIA Pharmaceuticals Inc.	ACAD	Biotechnology	34.46	10.3	29.00	300.0	3,476.9	8.6%	1.07	18.48	-15.8%	-0.9%	-17.4%	-36.3%
12.	1/6/2016	Sage Therapeutics, Inc.	SAGE	Spec Pharma	56.51	3.2	47.50	150.0	1,630.9	9.2%	0.39	30.58	-15.9%	-2.3%	-13.2%	-35.6%
13.	1/6/2016	TherapeuticsMD, Inc.	TXMD	Large Pharma	9.31	17.4	8.25	143.7	1,656.5	8.7%	3.11	6.00	-11.4%	5.7%	-8.1%	-27.3%
14.	1/5/2016	Accelaron Pharma Inc.	XLRN	Biotechnology	44.86	3.8	40.00	150.0	1,489.2	10.1%	0.28	24.18	-10.8%	-7.3%	-16.9%	-39.6%
15.	12/18/2015	Iradimed Corp.	IRMD	Med Tech	24.68	1.2	24.25	29.1	249.6	11.7%	0.09	17.85	-1.7%	7.0%	8.0%	-26.4%
16.	12/16/2015	Pfenex, Inc.	PFNX	Biotechnology	12.11	0.6	11.75	7.1	281.6	2.5%	0.09	7.56	-3.0%	3.7%	1.4%	-35.7%
17.	12/15/2015	Spark Therapeutics, Inc.	ONCE	Biotechnology	60.00	3.0	47.00	141.0	1,487.8	9.5%	0.26	32.00	-21.7%	-3.0%	-6.2%	-31.9%
18.	12/9/2015	Accelerate Diagnostics, Inc.	AXDX	Biotechnology	17.99	6.4	17.00	109.3	804.9	13.6%	0.17	11.42	-5.5%	21.8%	30.6%	-32.8%
19.	12/9/2015	Kite Pharma, Inc.	KITE	Biotechnology	74.85	4.2	69.00	287.6	3,291.9	8.7%	1.15	45.11	-7.8%	0.3%	-7.4%	-34.6%
20.	12/3/2015	T2 Biosystems, Inc.	TTOO	Biotechnology	11.77	3.7	9.75	36.0	239.4	15.0%	0.12	7.98	-17.2%	-5.1%	-1.8%	-18.2%
21.	12/3/2015	Portola Pharmaceuticals, Inc.	PTLA	Spec Pharma	49.38	3.1	48.00	150.0	2,602.6	5.8%	0.38	28.23	-2.8%	2.1%	-1.1%	-41.2%
22.	11/17/2015	Wright Medical Group N.V.	WMGI	Med Tech	21.85	4.5	20.82	93.7	2,243.0	4.2%	1.09	17.69	-4.7%	5.9%	0.8%	-15.0%
23.	11/11/2015	Loxo Oncology, Inc.	LOXO	Biotechnology	26.75	2.9	26.50	76.2	446.4	17.1%	0.29	18.86	-0.9%	4.7%	18.9%	-28.8%
24.	11/10/2015	WVR Corp.	WVR	Med Tech	27.21	12.7	25.75	325.7	3,574.3	9.1%	1.25	24.18	-5.4%	-0.7%	1.9%	-6.1%
25.	11/6/2015	Cancer Genetics, Inc.	CGIX	HC Services	6.50	3.0	4.00	12.0	64.0	18.8%	0.43	2.09	-38.5%	-2.3%	-3.5%	-47.8%
26.	11/3/2015	Revance Therapeutics, Inc.	RVNC	Spec Pharma	39.17	3.3	36.00	117.0	952.3	12.3%	0.72	18.56	-8.1%	2.3%	9.4%	-48.4%
27.	10/22/2015	Oasmia Pharmaceutical AB	OASM	Spec Pharma	4.50	2.6	4.06	10.4	146.8	7.1%	0.05	3.73	-9.8%	-3.9%	5.7%	-8.1%
28.	10/22/2015	Vital Therapies Inc.	VTIL	Biotechnology	5.51	6.3	5.50	34.5	132.3	26.1%	0.56	8.11	-0.2%	24.9%	41.3%	47.5%
29.	10/6/2015	Sarepta Therapeutics, Inc.	SRPT	Biotechnology	41.79	3.3	39.00	126.8	1,734.9	7.3%	2.28	14.36	-6.7%	-2.6%	-15.5%	-63.2%
30.	9/24/2015	Concordia Healthcare Corp	CXRX	Spec Pharma	72.23	8.0	65.00	520.0	2,084.6	24.9%	0.54	30.08	-10.0%	-12.7%	-32.5%	-53.7%
31.	9/22/2015	Intra-Cellular Therapies, Inc.	ITCI	Biotechnology	50.85	7.9	43.50	345.2	1,781.9	19.4%	0.86	27.71	-14.5%	10.0%	-8.0%	-36.3%
32.	9/17/2015	Sientra, Inc.	SIEN	Med Tech	23.15	3.0	22.00	66.0	345.9	19.1%	0.77	6.71	-5.0%	-8.2%	-54.1%	-69.5%
33.	9/15/2015	Mirati Therapeutics, Inc.	MRTX	Biotechnology	46.29	2.3	45.00	101.3	756.7	13.4%	0.35	22.06	-2.8%	-1.5%	-23.1%	-51.0%
34.	9/10/2015	Aquinox Pharmaceuticals, Inc	AQXP	Biotechnology	15.70	6.3	15.50	98.0	168.4	58.2%	0.45	10.01	-1.3%	6.2%	15.6%	-35.4%
35.	9/10/2015	Seattle Genetics, Inc.	SGEN	Biotechnology	41.29	13.5	41.00	552.0	5,173.7	10.7%	1.24	30.10	-0.7%	9.8%	15.5%	-26.6%
36.	8/21/2015	Intrexon Corp.	XON	Biotechnology	42.50	5.6	41.00	230.0	4,663.5	4.9%	2.10	31.55	-3.5%	10.9%	14.0%	-23.0%
37.	8/18/2015	Benitec Biopharma Limited	BNTC	Biotechnology	10.00	1.6	9.21	14.5	57.9	25.0%	0.02	3.50	-7.9%	-13.5%	-13.1%	-62.0%
38.	8/12/2015	Inotek Pharmaceuticals Corp	ITEK	Biotechnology	12.99	6.2	12.75	79.2	272.8	29.0%	0.46	6.99	-1.8%	11.9%	12.5%	-45.2%
39.	8/12/2015	INC Research Holdings, Inc.	INCR	HC Services	50.03	8.0	44.75	358.0	2,659.8	13.5%	0.44	38.97	-10.6%	0.3%	-1.9%	-12.9%
40.	8/5/2015	Dermira, Inc.	DERM	Biotechnology	24.37	5.2	21.50	111.3	601.2	18.5%	0.18	23.08	-11.8%	13.6%	17.5%	7.3%
41.	8/5/2015	Corium International Inc.	CORI	Biotechnology	16.10	4.0	13.00	52.0	292.4	17.8%	0.12	4.48	-19.3%	-6.9%	-7.9%	-65.5%
42.	8/4/2015	Intec Pharma Ltd.	NTEC	Spec Pharma	7.42	5.0	6.00	30.2	42.9	70.3%	0.02	3.76	-19.1%	0.5%	0.7%	-37.4%
43.	8/4/2015	Integra LifeSciences Holdings Corp.	IART	Med Tech	64.08	3.3	61.00	201.3	2,125.1	9.5%	0.34	59.59	-4.8%	2.0%	0.8%	-2.3%
44.	7/31/2015	Quintiles Transnational Holdings Inc.	Q	HC Services	78.75	7.0	77.85	545.0	9,663.3	5.6%	0.91	62.86	-1.1%	-1.5%	-3.3%	-19.3%
45.	7/30/2015	EyeGate Pharmaceuticals, Inc.	EYEG	Spec Pharma	12.00	1.2	8.50	10.0	76.9	13.0%	0.10	2.77	-29.2%	-0.2%	-0.4%	-67.4%
46.	7/30/2015	Zogenix, Inc.	ZGNX	Spec Pharma	20.14	5.5	18.00	98.3	386.1	25.5%	0.47	10.41	-10.6%	7.3%	5.1%	-42.2%
47.	7/30/2015	AMAG Pharmaceuticals, Inc.	AMAG	Biotechnology	64.95	3.6	63.75	230.9	2,004.9	11.5%	1.31	26.89	-1.8%	0.2%	2.1%	-57.8%
48.	7/29/2015	Cara Therapeutics, Inc.	CARA	Biotechnology	19.78	4.3	18.60	80.5	451.7	17.8%	0.37	6.91	-6.0%	4.8%	19.1%	-62.8%
49.	7/23/2015	Exelixis, Inc.	EXEL	Biotechnology	6.05	25.0	5.40	135.0	1,185.9	11.4%	5.59	3.82	-10.7%	3.5%	6.1%	-29.3%
50.	7/22/2015	Radius Health, Inc.	RDUS	Biotechnology	78.29	4.7	74.00	345.0	3,283.2	10.5%	1.05	30.92	-5.5%	2.8%	1.7%	-58.2%
51.	7/22/2015	Fibrocell Science, Inc.	FCSC	Biotechnology	5.85	2.6	5.80	15.0	239.3	6.3%	0.28	2.13	-0.9%	15.9%	9.3%	-63.3%
52.	7/21/2015	Exact Sciences Corp.	EXAS	Biotechnology	27.03	7.0	25.50	178.5	2,403.3	7.4%	3.12	5.80	-5.7%	-0.8%	-3.9%	-77.3%
53.	7/17/2015	Discovery Laboratories, Inc.	DSCO	Biotechnology	8.54	4.8	8.40	40.2	26.8	150.2%	0.04	2.10	-1.6%	0.0%	-11.7%	-75.0%
54.	7/16/2015	NephroGenex, Inc.	NRX	Biotechnology	8.73	1.6	5.00	8.1	77.4	10.4%	0.06	0.64	-42.7%	-17.6%	-20.2%	-87.2%
55.	7/16/2015	Delcath Systems, Inc.	DCTH	Med Tech	0.83	9.4	0.75	7.0	10.3	68.2%	0.36	0.27	-9.6%	-28.0%	-26.7%	-64.1%
56.	7/16/2015	RedHill Biopharma Ltd.	RDHL	Biotechnology	17.68	2.7	16.25	44.5	176.1	25.3%	0.06	9.35	-8.1%	0.0%	3.9%	-42.5%
57.	7/15/2015	NeuroDerm Ltd.	NDRM	Spec Pharma	15.59	4.5	17.00	76.9	265.0	29.0%	0.25	12.44	9.0%	9.6%	9.6%	-26.8%
58.	7/15/2015	DBV Technologies SA	DBVT	Biotechnology	30.51	8.3	34.00	281.5	1,185.8	23.7%	0.22	25.60	11.4%	22.1%	25.7%	-24.7%
59.	7/15/2015	Ultragenyx Pharmaceutical Inc.	RARE	Biotechnology	126.92	2.5	120.00	303.6	4,519.9	6.7%	0.51	60.85	-5.5%	4.1%	11.2%	-49.3%
60.	7/14/2015	MacroGenics, Inc.	MGNX	Biotechnology	39.44	3.5	37.00	130.4	1,188.1	11.0%	0.36	15.28	-6.2%	-1.7%	5.0%	-58.7%
61.	7/9/2015	Alara Biotherapeutics, Inc.	ATRA	Biotechnology	51.55	4.0	52.00	207.0	1,255.8	16.5%	0.35	15.67	0.9%	4.2%	15.2%	-69.9%
62.	7/8/2015	K2M Group Holdings, Inc.	KTWO	Med Tech	24.18	4.5	22.60	101.7	957.7	10.6%	0.24	12.22	-6.5%	-0.2%	6.5%	-45.9%
63.	7/8/2015	Clovis Oncology, Inc.	CLVS	Biotechnology	85.76	3.5	78.00	275.0	2,921.2	9.4%	1.35	17.29	-9.0%	0.3%	12.0%	-77.8%
							Mean	\$142.1	\$1,368.7	18.5%	0.7		-10.3%	1.5%	-0.6%	-37.3%
							Median	\$101.7	\$756.7	12.3%	0.4		-7.9%	0.3%	0.8%	-36.3%
							High	\$552.0	\$9,663.3	150.2%	5.6		11.4%	24.9%	41.3%	47.5%
							Low	\$5.0	\$10.3	2.5%	0.0		-42.7%	-28.0%	-54.1%	-87.2%

Source: BioCentury Publications, FactSet Research Systems, Ipreo, Private Raise and SEC filings as of February 26, 2016



FOLLOW-ON MARKET UPDATE (CONT'D)

Confidentially Marketed Public Offerings – Since 7/1/15

(Values in millions, except per share data)				Filing	Offering		Pre Deal	Proceeds /			Current	% Change	% Change Since Offering			
Date	Company	Ticker	Industry	Price	Shares	Price		Proceeds	Mkt. Cap.	Mkt. Cap.	3M ADTV	Price	File / Offer	1 Day	1 Week	Current
1.	2/10/2016	Mast Therapeutics, Inc	MSTX	Biotechnology	\$7.12	29.1	\$0.28	\$8.0	\$68.7	11.6%	1.33	\$0.28	-34.5%	-16.7%	3.6%	3.2%
2.	1/29/2016	ImmuCell Corporation	ICCC	Med Tech	7.74	1.1	5.25	5.9	23.6	25.0%	0.01	5.97	-32.2%	11.8%	17.5%	13.7%
3.	1/22/2016	Agile Therapeutics, Inc.	AGRX	Spec Pharma	7.06	6.3	6.35	40.3	157.4	25.6%	0.08	5.86	-10.1%	5.0%	-3.9%	-7.7%
4.	1/7/2016	pSivida Corp.	PSDV	Biotechnology	4.13	4.4	4.00	17.8	122.4	14.5%	0.70	2.74	-3.1%	8.3%	-12.5%	-31.5%
5.	1/7/2016	Galena Biopharma, Inc.	GALE	Biotechnology	1.29	19.8	1.10	21.7	183.3	11.9%	1.33	0.83	-14.7%	-15.5%	-32.7%	-24.1%
6.	12/16/2015	Sunesis Pharmaceuticals, Inc.	SNSS	Biotechnology	0.83	11.0	0.84	9.2	62.6	14.7%	0.32	0.74	1.2%	3.8%	13.7%	-11.9%
7.	12/9/2015	Aeterna Zentaris Inc.	AEZS	Biotechnology	7.10	3.2	5.54	17.9	49.2	36.4%	6.15	3.12	-22.0%	-13.5%	-16.1%	-43.7%
8.	11/13/2015	Alcobra Ltd.	ADHD	Spec Pharma	7.12	6.2	6.50	40.1	150.8	26.6%	0.40	4.78	-8.7%	-3.8%	-4.3%	-26.5%
9.	11/6/2015	Marinus Pharmaceuticals, Inc.	MRNS	Spec Pharma	7.73	5.0	6.00	30.0	110.8	27.1%	0.36	4.20	-22.4%	-5.8%	-10.3%	-30.0%
10.	11/3/2015	Vascular Biogenics, LTD	VBLT	Biotechnology	6.38	2.5	6.00	15.0	127.3	11.8%	0.21	3.35	-6.0%	0.2%	-3.7%	-44.2%
11.	10/7/2015	ContraVir Pharmaceuticals, Inc.	CTRV	Spec Pharma	3.99	5.0	3.00	15.0	89.0	16.9%	0.51	0.94	-24.8%	5.7%	-21.0%	-68.7%
12.	10/1/2015	Medgenics, Inc.	MDGN	Biotechnology	7.82	7.1	6.50	46.0	194.9	23.6%	0.22	4.10	-16.9%	0.9%	9.7%	-36.9%
13.	9/11/2015	Trevena, Inc.	TRVN	Biotechnology	10.35	7.5	9.75	72.9	435.3	16.7%	0.86	9.02	-5.8%	5.1%	36.4%	-7.5%
14.	9/9/2015	La Jolla Pharmaceutical Co.	LJPC	Biotechnology	42.31	2.9	38.00	111.4	645.3	17.3%	0.31	15.48	-10.2%	1.2%	2.3%	-59.3%
15.	8/18/2015	MediciNova Inc.	MNOV	Biotechnology	3.52	5.0	3.50	17.5	87.6	20.0%	0.07	6.42	-0.6%	-3.4%	-18.6%	83.4%
16.	8/13/2015	LDR Holding Corp.	LDRH	Med Tech	42.39	2.3	40.00	92.0	1,131.3	8.1%	0.44	20.72	-5.6%	1.4%	1.0%	-48.2%
17.	7/30/2015	Genocoe Biosciences, Inc.	GNCA	Biotechnology	13.91	3.9	13.00	50.1	335.8	14.9%	0.35	3.78	-6.5%	-1.4%	0.1%	-70.9%
18.	7/28/2015	Egalet Corp.	EGLT	Spec Pharma	11.52	7.7	11.25	86.3	199.6	43.2%	0.15	7.22	-2.3%	1.8%	3.6%	-35.8%
19.	7/22/2015	Dynavax Technologies Corp.	DVAX	Biotechnology	27.77	5.2	27.50	143.8	803.3	17.9%	0.59	17.73	-1.0%	6.8%	7.8%	-35.5%
20.	7/21/2015	CytRx Corp.	CYTR	Spec Pharma	3.80	10.5	2.75	28.8	212.5	13.5%	0.73	2.60	-27.6%	10.5%	3.3%	-5.5%
21.	7/17/2015	TrovaGene Inc.	TROV	Biotechnology	10.13	4.6	8.75	40.3	253.2	15.9%	0.59	5.50	-13.6%	8.8%	-2.6%	-37.1%
22.	7/16/2015	Synthetic Biologics Inc.	SYN	Biotechnology	3.76	15.3	3.00	46.0	275.2	16.7%	1.53	1.51	-20.2%	4.0%	13.3%	-49.7%
23.	7/15/2015	Cymbabay Therapeutics, Inc.	CBAY	Biotechnology	2.81	8.2	2.81	23.0	42.9	53.7%	0.23	1.18	0.0%	-3.9%	6.8%	-58.0%
24.	7/14/2015	Tonix Pharmaceuticals Holding Corp.	TNXP	Spec Pharma	8.24	2.7	7.50	20.1	133.1	15.1%	0.19	2.77	-9.0%	-0.4%	25.1%	-63.1%
25.	7/14/2015	Vermillion, Inc.	VRML	Biotechnology	2.04	9.6	1.96	18.8	86.2	21.8%	0.04	1.37	-3.9%	-0.5%	5.1%	-30.1%
26.	7/9/2015	Anthera Pharmaceuticals, Inc.	ANTH	Biotechnology	8.34	3.8	7.50	28.8	298.7	9.6%	0.94	2.92	-10.1%	-0.4%	21.7%	-61.1%
27.	7/7/2015	EnteroMedics Inc.	ETRM	Med Tech	0.58	32.0	0.50	16.0	13.9	115.5%	0.09	1.07	-13.8%	-24.0%	-20.0%	114.0%
						Mean	\$39.4	\$233.1	23.9%	0.7		-12.0%	-0.5%	0.9%		-24.9%
						Median	\$28.8	\$150.8	16.9%	0.4		-10.1%	0.9%	2.3%		-35.5%
						High	\$143.8	\$1,131.3	115.5%	6.2		1.2%	11.8%	36.4%		114.0%
						Low	\$5.9	\$13.9	8.1%	0.0		-34.5%	-24.0%	-32.7%		-70.9%

Source: BioCentury Publications, FactSet Research Systems, Ipreo, Private Raise and SEC filings as of February 26, 2016



Healthcare Investment Banking

Richard Page
Head of Healthcare Investment Banking
(212) 829-3828
rpage@janney.com

James McNaughton
Managing Director
(215) 665-6032
jmcnaughton@janney.com

Benjamin McKean
Associate
(215) 665-4474
bmckean@janney.com

Dan Morrison
Analyst
(212) 665-6292
dmorrison@janney.com

Healthcare Equity Capital Markets

Sales and Trading

William Corkhill
Managing Director
(617) 557-2970
wcorkhill@janney.com

David Lau
Managing Director
(617) 557-2971
dlau@janney.com

Katherine O'Brien
Analyst
(617) 557-2979
katherineobrien@janney.com

Brian Donohue
Managing Director
(212) 759-6211
bdonohue@janney.com

Healthcare Equity Research

Research Analyst

Coverage Universe

Paul Knight, CFA
Life Sciences Technology
(212) 888-2696
pknight@janney.com

Agilent Technologies (A)
Bio-Techne (TECH)
Bruker (BRKR)
Cancer Genetics (CGIX)
CareDx (CDNA)
Danaher (DHR)
Foundation Medicine (FMI)
Harvard Bioscience (HBIO)
Illumina (ILMN)
Mesa Laboratories (MLAB)
Mettler-Toledo International (MTD)
Neogen (NEOG)

Neogenomics (NEO)
PerkinElmer (PKI)
Qiagen (QGEN)
Repligen (RGEN)
Safeguard Scientifics (SFE)
T2 Biosystems (TTOO)
Thermo Fisher Scientific (TMO)
Trovagene (TROV)
Veracyte (VCYT)
Waters (WAT)
West Pharmaceuticals (WEST)

Roy Buchanan, Ph.D.
Biotechnology
(212) 940-6985
rbuchanan@janney.com

Accelaron (XLRN)
Advaxis (ADXS)
Aldeyra Therapeutics (ALDX)
Amicus Therapeutics' (FOLD)
Clovis Oncology (CLVS)

Corcept Therapeutics (CORT)
Editas Medicine (EDIT)
Geron Corp (GERN)
Sangamo Biosciences (SGMO)
vTv Therapeutics (VTVT)

Debjit Chattopadhyay, Ph.D.
Biotechnology
(215) 665-6224
dchattopadhyay@janney.com

Bluebird Bio (BLUE)
Cempra (CEMP)
CERU (Cerulean)
Chimerix (CMRX)

MacroGenics (MGNX)
Nektar Therapeutics (NKTR)
Strongbridge Biopharma (SBBP)
uniQure (QURE)

Ken Trbovich, CFA
Specialty Pharmaceuticals
(215) 665-6290
ktrbovich@janney.com

Agile Therapeutics (AGRX)
BioDelivery Sciences (BDSI)
Cara Therapeutics (CARA)

DepoMed (DEPO)
Flexion Therapeutics (FLXN)

This material is a publication of Janney Montgomery Scott LLC's Investment Banking Department and for informational Purpose only and shall in no event be construed as an offer to sell or a solicitation of an offer to buy any securities. The views expressed in this publication may differ from those expressed by other areas of the Firm including the Firm's Research Department. To view the firm's current research on the Healthcare sector please go to www.janney.com. Janney Montgomery Scott LLC's Investment Banking Department is independent of the Firm's Research Department.

The factual information described herein is taken from sources which we believe to be reliable, but the accuracy and completeness of such information is not guaranteed by us. The opinions expressed herein may be given only such weight as opinions warrant. Opinions expressed are subject to change without notice and do not take into account the particular investment objectives, financial situations or needs of individual investors. This Firm, its officers, directors, employees, or members of their families may have positions in the securities mentioned and may make purchases or sales of such securities from time to time in the open market or otherwise and may sell to or buy from customers such securities on a principal basis. Supporting information related to the recommendation, if any, made in this material is available upon request.

Janney Montgomery Scott LLC is a registered broker-dealer member of FINRA, NYSE, and SIPC.